Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

Participants who had received three doses of BNT162b2 vaccine received either a fourth dose or a bivalent vaccine containing BA.4–BA.5 mRNA; the latter group had higher neutralization against omicron variants.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine Jg. 388; H. 9; S. 854 - 857
Hauptverfasser: Zou, Jing, Kurhade, Chaitanya, Patel, Sohil, Kitchin, Nicholas, Tompkins, Kristin, Cutler, Mark, Cooper, David, Yang, Qi, Cai, Hui, Muik, Alexander, Zhang, Ying, Lee, Dung-Yang, Şahin, Ugur, Anderson, Annaliesa S., Gruber, William C., Xie, Xuping, Swanson, Kena A., Shi, Pei-Yong
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Massachusetts Medical Society 02.03.2023
Schlagworte:
Antibodies
Antibodies, Neutralizing - immunology
Antibodies, Viral - immunology
Confidence intervals
Coronavirus
Coronaviruses
Correspondence
COVID-19 - immunology
COVID-19 - therapy
COVID-19 - virology
COVID-19 Vaccines - immunology
COVID-19 Vaccines - therapeutic use
Humans
Infections
Infectious Disease
mRNA
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
Vaccines
Vaccines, Combined - immunology
Vaccines, Combined - therapeutic use
Viral Infections
Viruses
United States > US
ISSN:0028-4793, 1533-4406, 1533-4406
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Participants who had received three doses of BNT162b2 vaccine received either a fourth dose or a bivalent vaccine containing BA.4–BA.5 mRNA; the latter group had higher neutralization against omicron variants.
Bibliographie:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
content type line 23
Drs. Zou and Kurhade contributed equally to this letter.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2214916